Results 151 to 160 of about 213,634 (311)

Impact of empiric potassium supplementation on mortality, sudden cardiac arrest and stroke in furosemide initiators

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen   +8 more
wiley   +1 more source

Stimulation of angiotensin II type 2 receptor attenuates organ injury in rats with polymicrobial sepsis. [PDF]

open access: yesJ Chin Med Assoc, 2023
Shih CC   +6 more
europepmc   +1 more source

Mitral Transcatheter Edge‐to‐Edge Repair in Patients With Advanced Heart Failure: A Single‐Center Experience and Insights Into Anatomical and Clinical Determinants of Procedural Complexity

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Advanced heart failure (HF) remains a clinical challenge, and mitral transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a potential bridging strategy. Aims To describe the clinical outcomes of M‐TEER in a single‐center cohort of patients with advanced HF and to identify anatomical and clinical features potentially associated ...
Pedro Castilhos de Freitas Crivelaro   +8 more
wiley   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

open access: yesHepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah   +2 more
wiley   +1 more source

Variability in ACT Response to Standard UFH Bolus During PCI: A Prospective Study on Determinants of Subtherapeutic Anticoagulation

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu   +9 more
wiley   +1 more source

A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's. [PDF]

open access: yesRheumatology (Oxford), 2023
Herrick AL   +7 more
europepmc   +1 more source

Synergistic Effects of Normal‐Range Serum Sodium and Potassium on Mortality: The Modifying Role of Inflammation From a NHANES Cohort Analysis

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Nonlinear associations of serum sodium levels with cardiovascular (A) and all‐cause mortality (B)among 32,837 adults. Nonlinear associations of serum potassium levels with cardiovascular (C) and all‐cause mortality (D) among 32,837 adults. ABSTRACT Background This study aimed to investigate the associations of serum sodium and potassium levels within ...
Haofeng Zhang   +7 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

open access: yesHepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres   +21 more
wiley   +1 more source

Angiotensin II type-2-receptor stimulation ameliorates focal and segmental glomerulosclerosis in mice. [PDF]

open access: yesClin Sci (Lond), 2022
Liao MC   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy